The effect of cryoprecipitate and fibrinogen concentrate for treating postpartum hemorrhage: a descriptive study

The effect of cryoprecipitate and fibrinogen concentrate for treating postpartum hemorrhage: a descriptive study - Descriptive comparison of cryoprecipitate and fibrinogen concentrate for treating PPH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042842

Enrollment

Registered

2020-12-28

Start date

2020-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum hemorrhage

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women who delivered at Juntendo University Hospital from April 2015 to August 2020, and had all the criteria below: had postpartum hemorrhage, severe hemorrhage over 2,000 mL or acquired hypofibrinogenemia less then 200 mg / dL, and treated with cryoprecipitate or fibrinogen concentrate.

Exclusion criteria

Exclusion criteria: Exclusion criteria were women with congenital hypofibrinogenemia, artificial abortion, or miscarriage.

Design outcomes

Primary

Measure	Time frame
Volume of transfusion after cryoprecipitate or fibrinogen concentrate	—

Secondary

Measure	Time frame
Total bleeding volume, transfusion of RBC, FFP, or platelet, coagulation parameters	—

Countries

Japan

Contacts

Public ContactHisako Okada

Juntendo University Faculty of Medicine Department of Anesthesiology and Pain Medicine

h-okada@juntendo.ac.jp03-3813-3111

Outcome results